Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2022

Summary of Significant Accounting Policies

Reconciliation of the cash, cash equivalents and restricted cash

	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	55,850	$	98,635
Restricted cash, included in other assets		5,000		5,000
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	60,850	$	103,635

Schedule of the Company's net sales by medical indication

	Three Months Ended				Six Months Ended
(In thousands)	December 31,				December 31,
Medical Indication	2022		2021		2022		2021
Analgesic	$	2,592	$	3,919	$	6,016	$	9,233
Anti-Psychosis		2,575		2,095		5,195		5,810
Cardiovascular		13,089		9,753		23,971		23,853
Central Nervous System		21,782		22,340		42,576		45,125
Endocrinology		5,831		8,297		13,143		16,142
Gastrointestinal		8,716		14,023		16,658		29,263
Infectious Disease		4,989		6,520		10,058		19,035
Migraine		3,574		4,446		6,898		9,131
Respiratory/Allergy/Cough/Cold		1,468		1,868		2,670		4,982
Other		10,955		10,275		19,714		20,627
Contract manufacturing revenue		5,323		2,972		9,074		4,832
Total net sales	$	80,894	$	86,508	$	155,973	$	188,033

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2022		2021		2022		2021
Customer A	22	%	26	%	22	%	28	%
Customer B	21	%	15	%	21	%	17	%
Customer C	16	%	14	%	16	%	14	%